Blood Compatibility Screening
Blood Compatibility Screening - Related Videos
07:52
Revised and Neuroimaging-Compatible Versions of the Dual Task Screen
0 Views •
Cited by 4 •
2020
We developed the original Dual Task Screen (DTS) as a portable, low-cost measure that can evaluate athletes with sports-induced mild traumatic brain injury. We revised the original DTS for future clinical use and developed a neuroimaging-compatible version of the DTS to measure neural underpinnings of single and dual task performance.
08:48
Applications for Open Source Microplate-Compatible Illumination Panels
0 Views •
2019
Microplate Assistive Pipetting Light Emitter (M.A.P.L.E.) is a computer-driven device that systematically illuminates microtiter wells to provide guidance for the manual preparation of microplates. M.A.P.L.E. improves the accuracy of microplate preparation while automating data recordkeeping. In addition, it can assist with examining microplate quality or aid in the detection of errors.
08:40
Chemical Storage: Categories, Hazards And Compatibilities
0 Views •
2023
Source: Robert M. Rioux & Taslima A. Zaman, Pennsylvania State University, University Park, PA While the use of various chemicals in experimental research is essential, it is also important to safely store and maintain them as a part of the Environmental, Health and Safety (EHS) program. The properties of chemicals and their reactivity vary broadly and if chemicals are not managed, stored, and labeled properly, they can have harmful or even destructive consequences such as toxic fume...
07:12
Determination of Self-(In)compatibility and Inter-(In)compatibility Relationships in Citrus Using Manual Pollination, Microscopy, and S-Genotype Analyses
0 Views •
2023
This protocol provides a rapid method for determining pollen compatibility and incompatibility in citrus cultivars.
10:29
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
0 Views •
Cited by 1 •
2017
New models and assays that would improve the early drug development process for next-generation anti-tuberculosis drugs are highly desirable. Here, we describe a quick, inexpensive, and BSL-2 compatible assay to evaluate drug efficacy against Mycobacterium tuberculosis that can be easily adapted for high-throughput screening.
FAQs
ABO and Rh factors identify important red blood cell antigens that can differ between a donor and recipient. Because these surface markers influence whether the recipient’s immune system recognizes transfused cells as compatible, testing them helps guide blood-product selection. Considering both systems provides a more informative compatibility assessment than relying on a single blood-group characteristic.
Agglutination occurs when antibodies interact with matching antigens on red blood cells, causing the cells to clump. During compatibility testing, visible clumping indicates that an immune reaction may occur if the samples are combined in the body. Detecting this reaction in the laboratory allows incompatible donor-recipient combinations to be identified before transfusion decisions are made.
Antibody screening looks for antibodies that could react with red blood cell antigens, while crossmatching combines donor and recipient samples to assess their direct compatibility. These tests provide complementary information: screening identifies a potential immune factor, and crossmatching evaluates the specific proposed pairing. Together, they support more informed selection of blood products for a recipient.
A donor sample and a recipient sample can each appear acceptable when considered separately, yet their combination may reveal an antibody-antigen reaction. Testing them together exposes incompatibility that may not be evident from blood-group identification alone. This comparison is therefore important for detecting reactions before administration and for reducing the likelihood of a hemolytic transfusion reaction.
The workflow begins with identifying relevant red blood cell antigens, particularly ABO and Rh factors. Laboratory personnel then perform antibody screening and combine donor and recipient samples for crossmatching. Observing the combined samples for agglutination or other incompatibility provides evidence used to select suitable blood products. These stages connect blood-group information with a direct compatibility assessment.
Blood compatibility screening also contributes to decisions involving organ transplantation and the evaluation of maternal-fetal blood group incompatibility. In each setting, differences in blood-group antigens and antibodies can have biological consequences, so compatibility information helps assess immune-related risk. The same underlying laboratory observations, including antigen identification and incompatibility detection, provide context for these broader biological and clinical decisions.